Zobrazeno 1 - 10
of 489
pro vyhledávání: ''
Autor:
Nicolas Freynet, Hervé Dombret, Daniel Lusina, Emmanuel Benayoun, Xavier Thomas, Estelle Guérin, Raphael Itzykson, Pascal Turlure, Claude Preudhomme, Laurène Fenwarth, Christine Terré, Aline Renneville, Elise Fournier, Thomas Boyer, Bouchra Badaoui, Isabel Garcia, Cécile Pautas, Thomas Cluzeau, Claude Gardin, Orianne Wagner-Ballon, Matthieu Duchmann, Juliette Lambert, Pierre Fenaux, Meyling Cheok, Bruno Quesnel
Publikováno v:
Leukemia. 36:656-663
The independent prognostic impact of specific dysplastic features in acute myeloid leukemia (AML) remains controversial and may vary between genomic subtypes. We apply a machine learning framework to dissect the relative contribution of centrally rev
Autor:
Raymond E. Baser, Tina Paul, Dristi Talukder, Mary Lou Galantino, Lillian M. Zhi, W. Iris Zhi, Qing S. Li, Clare Patterson, Christina Seluzicki, Lauren Piulson, Ting Bao
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 16, Pp 5456-5465 (2021)
Cancer Medicine, Vol 10, Iss 16, Pp 5456-5465 (2021)
Background Yoga is a meditative movement therapy focused on mind‐body awareness. The impact of yoga on health‐related quality of life (HRQOL) outcomes in patients with chemotherapy‐induced peripheral neuropathy (CIPN) is unclear. Methods We con
Autor:
Joyce Cheng, Whitney S. Helms, Adnan A. Jaigirdar, Marc R. Theoret, Kwadwo Korsah, Atiqur Rahman, Julia A. Beaver, Rajiv Agarwal, Salaheldin S. Hamed, Hong Zhao, Harpreet Singh, Anwar Goheer, Yangbing Li, Jiang Liu, Sonia Singh, John K. Leighton, Xing Wang, Richard Pazdur, Shenghui Tang, Flora Mulkey, Rajan Pragani
Publikováno v:
Clin Cancer Res
On June 15, 2020, the FDA granted accelerated approval to lurbinectedin for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy. Approval was granted on the ba
Autor:
Dimopoulos, M. A., Špička, I., Quach, H., Oriol, Albert, Hájek, R., Garg, M., Beksac, M., Bringhen, S., Katodritou, E., Chng, W. J., Leleu, X., Iida, S., Mateos, M. V., Morgan, G., Vorog, A., Labotka, R., Wang, B., Palumbo, A., Lonial, S., Universitat Autònoma de Barcelona
Publikováno v:
Journal of Clinical Oncology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Digital.CSIC. Repositorio Institucional del CSIC
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Digital.CSIC. Repositorio Institucional del CSIC
© 2020 by American Society of Clinical Oncology.
[Purpose]: Maintenance therapy prolongs progression-free survival (PFS) in patients with newly diagnosed multiple myeloma (NDMM) not undergoing autologous stem cell transplantation (ASCT) but has
[Purpose]: Maintenance therapy prolongs progression-free survival (PFS) in patients with newly diagnosed multiple myeloma (NDMM) not undergoing autologous stem cell transplantation (ASCT) but has
Autor:
Takashi Ikeda, Kenichi Ishizawa, Chihiro Shimazaki, Keishiro Takahashi, Hirohiko Shibayama, Hitomi Kaneko, Hirokazu Murakami, Dai Maruyama, Michihiro Uchiyama, Hélène Guillemin-Paveau, Toru Kiguchi, Kazutaka Sunami, Sandrine Macé, Masaki Ri, Hideki Asaoku, Hiroyuki Takamatsu, Morio Matsumoto, Keisuke Tada, Kenshi Suzuki, Satoshi Iyama, Shinsuke Iida
Publikováno v:
Cancer Science
Isatuximab, an anti‐CD38 monoclonal antibody, targets cells that strongly express CD38 including malignant plasma cells. This open‐label, single‐arm, multicenter, phase 1/2 trial investigated the tolerability/safety and efficacy of isatuximab m
Autor:
Sarah Attwell, David M. Nanus, Eric Campeau, Sanjay Lakhotia, Margo Snyder, Michael T. Schweizer, Lisa Bauman, Rahul Aggarwal, Allan J. Pantuck, Joshi J. Alumkal, Felix Y. Feng, Elisabeth I. Heath, Eric J. Small, Wassim Abida, Karen Norek
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 26, iss 20
Purpose:ZEN-3694 is a bromodomain extraterminal inhibitor (BETi) with activity in androgen-signaling inhibitor (ASI)-resistant models. The safety and efficacy of ZEN-3694 plus enzalutamide was evaluated in a phase Ib/IIa study in metastatic castratio
Autor:
Yuanyuan Ma, Xuguang Song, Feng Zhu, Hai Cheng, Haiying Sun, Depeng Li, Jiang Cao, Meixue Yao, Jingjing Yang, Kailin Xu, Ming Shi, Weidong Li, Cai Sun, Hui Liu, Jun Jiao, Mei Wu, Yuanyuan Qin, Linyan Xu, Kemeng Sun, Xiang Gao, Ying Wang, Junnian Zheng, Zhenyu Li, Bing Zhang, Lingyu Zeng, Zhiling Yan, Dongmei Yan, Tingting Sang, Wei Sang
Publikováno v:
Cancer Medicine, Vol 9, Iss 16, Pp 5827-5838 (2020)
Cancer Medicine
Cancer Medicine
Purpose Anti‐CD19 chimeric antigen receptor T (CAR‐T) cell therapy has demonstrated remarkable efficacy for refractory and relapsed diffuse large B cell lymphoma (R/R DLBCL). However, this therapy failed in nearly 25% patients mainly due to antig
Autor:
Marek Dudziński, Monika Długosz-Danecka, Małgorzata Wojciechowska, Michal Osowiecki, Elżbieta Iskierka-Jażdżewska, Weronika Piszczek, Jan Maciej Zaucha, Agnieszka Szymczyk, Edyta Subocz, Joanna Drozd-Sokołowska, Anna Waszczuk-Gajda, Beata Kumiega, Krzysztof Giannopoulos, Ryszard Wichary, Marek Hus, Bartosz Pula, Wojciech Jurczak, Tadeusz Robak, Bożena Katarzyna Budziszewska, Janusz Hałka, Wanda Knopinska-Posluszny, Krzysztof Jamroziak, Agnieszka Szeremet, Andrzej Pluta, Daria Zawirska, Paweł Steckiewicz, Jadwiga Hołojda, Ewa Lech-Marańda
Publikováno v:
Anticancer Research. 40:4059-4066
Background/aim To study the long-term clinical efficacy and tolerability of ibrutinib monotherapy in real-world relapsed and refractory chronic lymphocytic leukemia (RR-CLL) patients outside clinical trials. Patients and methods Clinical data of 171
Autor:
Courtney D. DiNardo, Lewis R. Silverman, Charles Cai, Claudia D. Baldus, Isabelle Genvresse, Eleni Lagkadinou, Neil Palmisiano, Walter Fiedler, Alice S. Mims, Michael Jeffers, Markus Wagner, Ioannis Mantzaris, Alexander E. Perl, Gary Wilkinson, Bingyan Wu, Christine Rentzsch, Eunice S. Wang, Timothy S. Pardee, Sebastian Schwind, Stefan Kaulfuss, Michael Heuser, Alwin Krämer
Publikováno v:
Leukemia
The mutant IDH1 (mIDH1) inhibitor BAY1436032 demonstrated robust activity in preclinical AML models, supporting clinical evaluation. In the current dose-escalation study, BAY1436032 was orally administered to 27 mIDH1 AML subjects across 4 doses rang
Autor:
Mihaela Druta, Steven Attia, Michael Chen, Dejka M. Araujo, Chet Bohac, Sant P. Chawla, Neeta Somaiah, Melissa Amber Burgess, Brian A. Van Tine, Scott H. Okuno, Sergey Yurasov, Seth M. Pollack, Mahesh Seetharam
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 9, Iss 13, Pp 4593-4602 (2020)
Cancer Medicine, Vol 9, Iss 13, Pp 4593-4602 (2020)
Background Outcomes data regarding advanced synovial sarcoma (SS) and myxoid/round cell liposarcoma (MRCL) are limited, consisting primarily of retrospective series and post hoc analyses of clinical trials. Methods In this multi‐center retrospectiv